Which peptides are studied for hormone conditions?
Short answer
25 profiles here are grouped under “Hormones”: 16 FDA-approved and 9 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 16
Mecasermin
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides
Not FDA-approved 9
Unapproved new drug in cited enforcement record38
Not FDA-approved. FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among compounding substances that may present significant safety risks.39,40
Is CJC-1295 FDA-approved? · CJC-1295 vs Ipamorelin · CJC-1295 vs Sermorelin
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)40
No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.40,41
Is GHRP-2 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-2 vs Ipamorelin
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)40
No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-6 in category 2 under its interim policy for outsourcing facilities, for substances that may present significant safety risks.40
Is GHRP-6 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-6 vs Ipamorelin
IGF-1 LR3
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides
Unapproved new drug in cited enforcement record38
Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.40,44
Is ipamorelin FDA-approved? · CJC-1295 vs Ipamorelin · Ipamorelin vs Sermorelin
MK-677
Not a peptide: a small molecule often looked up alongside peptides
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)40,46
No FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.40,46
Is MK-677 FDA-approved? · MK-677 vs Ipamorelin · MK-677 vs Sermorelin
FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness47,48
Not FDA-approved. FDA withdrew the approvals of both Geref applications, NDA 019863 and NDA 020443, effective June 18, 2009, after the maker discontinued them, according to a 2013 Federal Register notice.47,48
Is sermorelin FDA-approved? · Sermorelin vs Tesamorelin · Ipamorelin vs Sermorelin
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1MIACALCIN (calcitonin salmon) injection, solution · SPL version 9 · published 2026-06-19 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA: MIACALCIN (calcitonin salmon), NDA 017808 · original approval July 3, 1986 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5DDAVP (desmopressin acetate) tablet · SPL version 7 · published 2025-12-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 6Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 7PARSABIV (etelcalcetide) injection, solution · SPL version 15 · published 2026-03-16 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 8Drugs@FDA: PARSABIV (etelcalcetide), NDA 208325 · original approval February 7, 2017 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 9Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 10Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 11Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 12Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 13ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 14Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 15SUPPRELIN LA (histrelin acetate) implant · SPL version 38 · published 2025-09-29 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 16Drugs@FDA: SUPPRELIN LA (histrelin acetate), NDA 022058 · original approval May 3, 2007 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 17Lanreotide acetate injection · SPL version 3 · published 2025-06-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 18Drugs@FDA application NDA022074 · original submission status AP · 2007-08-30 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 19Drugs@FDA application NDA215395 · original submission status AP · 2021-12-17 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 20Drugs@FDA application ANDA217193 · original submission status AP · 2024-05-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 21Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 22INCRELEX (mecasermin) injection · SPL version 4 · published 2025-11-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 23SYNAREL (nafarelin acetate) nasal solution · SPL version 23 · published 2026-03-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 24Drugs@FDA: SYNAREL (nafarelin acetate), NDA 019886 · original approval February 13, 1990 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 25Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 26Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 27Drugs@FDA application NDA021008 · original submission status AP · 1998-11-25 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 28Drugs@FDA application NDA208232 · original submission status AP · 2020-06-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 29Drugs@FDA application NDA213224 · original submission status AP · 2024-09-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 30PITOCIN (oxytocin) injection · SPL version 15 · published 2026-05-21 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 31Drugs@FDA: PITOCIN (oxytocin), NDA 018261 · original approval November 19, 1980 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 32YORVIPATH (palopegteriparatide) injection, solution · SPL version 10 · published 2026-11-09 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 33Drugs@FDA: YORVIPATH (palopegteriparatide), NDA 216490 · original approval August 9, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 34SIGNIFOR (pasireotide) injection · SPL version 20 · published 2026-02-18 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 35Drugs@FDA: SIGNIFOR (pasireotide diaspartate), NDA 200677 · original approval December 14, 2012 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 36TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 37Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 38Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 39FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 40Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 41Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 42Examorelin (hexarelin) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 43Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 44FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026
- 45FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 46October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 47Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗
Federal Register · Official source · Source checked November 15, 2026
- 48Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026